Novartis AG has reported new drug conjugates comprising drugs targeting fibroblast activation protein α (FAP) covalently linked to a radiolabeled chelating agent through a linker potentially useful for the treatment and/or diagnosis of cancer.
Prelude Therapeutics Inc. has identified new tyrosine-protein kinase JAK2 inhibitors potentially useful for the treatment of leukemia, polycythemia vera, myelofibrosis, essential thrombocythemia and graft-vs.-host disease.
Vastpro (Shanghai) Pharmaceutical Technology Development Co. Ltd. has patented new voltage-gated sodium channel blockers potentially useful for the treatment of pain.
Guangzhou Respiratory Medicine Engineering Technology Co. Ltd. has disclosed new cathepsin C (dipeptidyl peptidase I) and neutrophil elastase (ELANE; leukocyte elastase) inhibitors potentially useful for the treatment of asthma, diabetes, psoriasis, nasal polyps, cystic fibrosis and more.
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of neurodegeneration and inflammatory disorders.
Shanghai Peptidstar Therapeutics Ltd. has divulged new cyclic peptides acting as interleukin-23 receptor (IL-23R) antagonists potentially useful for the treatment of psoriasis, arthritis and inflammatory bowel disease.
K2 Medicines (Nanjing) Co. Ltd. has disclosed new epidermal growth factor receptor (EGFR; ERBB1; HER1) mutant inhibitors potentially useful for the treatment of cancer.
Anew Therapeutics Pte Ltd. has discovered new interleukin-17A (IL-17A)/interleukin-17 receptor A (IL-17RA) interaction inhibitors reported be useful for the treatment of Crohn’s disease, type 1 diabetes, dry eye and more.
RSS